NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Sage Therapeutics, Inc. ("Sage" or "the Company") (NasdaqGM: SAGE). Sage is a biopharmaceutical company that develops and commercializes brain health medicines. On April 17, 2024, the Company disclosed that a Phase 2 study of its SAGE-718 product "did not meet its primary endpoint of demonstrating statistically significant difference from baseline in participants treated with once-daily dalzanemdor [SAGE-718] versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition-IV Coding Test score at Day 42," and that, "[b]ased on the data, the Company does not plan any further development of [SAGE-718] in PD."